{"nct_id":"NCT01290887","title":"Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma","status":"TERMINATED","status_verified_date":"2016-04","start_date":"2011-06","start_date_type":null,"primary_completion_date":"2015-01","primary_completion_date_type":"ACTUAL","completion_date":"2015-01","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TEVA"]}